TeraDx

teradx.com ↗ ·Valencia ·Pre-seed

TeraDx is a Spanish medtech/biotech startup developing a non-invasive saliva test that uses oral microbiome biomarkers, qPCR and a proprietary algorithm to detect head and neck squamous cell carcinoma (HNSCC) early, delivering results in under 24 hours on standard hospital PCR equipment. Spun out of Dr. Vicente Navarro's microbiome research (Bioithas, UCAM Chair of Human Microbiota, FISABIO group MiBioPath), the company reports 97% sensitivity and 100% specificity in proof-of-concept studies and holds granted patents in Europe and Japan. It is very early stage (HQ in Valencia): impact venture builder Zubi Labs joined as strategic partner in late 2025, with a first institutional funding round planned for 2026 and CE marking targeted for 2027.

Founded

2024

Founders

Total funds raised

—

SectorsHealthtech & Bio, Deeptech & Hardware, Diagnostics, Oncology, Microbiome Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Suggest a correction

Founders

Iryna Biliaieva

Co-founder & COO

Isabel Jiménez González

CEO & Co-founder

Pol Hortal Pampalona

Co-founder & Board Member (Co-founder and Managing Director of Zubi Labs)

Vicente Navarro López

Co-founder & Chief Scientific Officer

Global models 5

GRAIL

United States · grail.com ↗

Develops a non-invasive molecular test for early cancer detection that combines biomarkers with a proprietary algorithm, sold to health systems and payers.

$2BComparable

Freenome

United States · www.freenome.com ↗

Early cancer detection test built on multiomics biomarkers and machine learning, aimed at clinical screening, the same diagnostic model as TeraDx.

$1.1BComparable

Guardant Health

United States · guardanthealth.com ↗

Built a non-invasive liquid-biopsy test for cancer detection and sold it into hospitals and oncology. This figure is funding raised before its IPO.

$550MComparable

Delfi Diagnostics

United States · delfidiagnostics.com ↗

Early cancer detection test that runs a proprietary algorithm on biomarkers from a simple sample, which mirrors TeraDx's test-plus-algorithm model.

$330MComparable

Viome

United States · www.viome.com ↗

Uses saliva and microbiome molecular analysis with AI for health tests, including CancerDetect for oral and throat cancer, the closest match to TeraDx's saliva-based head and neck cancer test.

$175MComparable

In the same niche 48 others

See all in the Start-ups Map →

Universal Diagnostics

Venture Debt · €25.7M

Biohope

Madrid

No stage disclosed · €15M

iPremom

Valencia

Seed · €15M

+42 more →

Notes: Most funded first

Investors 1

Open as list →

Zubi Labs

zubi.group

Led Pre-seed 2025 Spain

Funding rounds 1

Date	Round	Amount	Lead
2025-10-07	Pre-seed	—	Zubi Labs

News 2

Open as list →

Published	Article
2025-10-07	TeraDx and Zubi Labs Launch Rapid Saliva Test for Head and Neck Cancer ↗ Zubi Group (press release) +1 source 2 reportsfirst 2025-10-07 TeraDx and Zubi Labs Launch Rapid Saliva Test for Head and Neck CancerZubi Group (press release) · 2025-10-07↗ TeraDx: test de saliva para detectar el cáncer de cabeza y cuelloEmprendedores · 2025-10-12↗ 2025-10-07
2025-10-07	TeraDx joins forces with Zubi Labs to accelerate early cancer diagnosis ↗ Capital & Corporate (Capital-Riesgo.es) 2025-10-07